- Home
- Publications
- Publication Search
- Publication Details
Title
Current Advances in the Treatment of BRAF-Mutant Melanoma
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 2, Pages 482
Publisher
MDPI AG
Online
2020-02-24
DOI
10.3390/cancers12020482
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer
- (2019) Ying Cheng et al. INTERNATIONAL JOURNAL OF CANCER
- Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity
- (2019) Hiroshi Yano et al. IMMUNOLOGY
- A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
- (2019) Shubham Pant et al. JOURNAL OF CLINICAL ONCOLOGY
- A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
- (2019) Julia Katharina Schwarze et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
- (2019) Aasen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study
- (2018) Raoul Tibes et al. BRITISH JOURNAL OF CANCER
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
- (2018) Michael B. Atkins et al. CLINICAL CANCER RESEARCH
- Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
- (2018) Pauline Tétu et al. EUROPEAN JOURNAL OF CANCER
- Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
- (2018) G.M. Haag et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
- (2018) Margaret K. Callahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Warming “Cold” Melanoma with TLR9 Agonists
- (2018) Cancer Discovery
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
- (2018) Natalia Pieper et al. OncoImmunology
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
- (2018) Allison S. Dobry et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Encorafenib and Binimetinib: First Global Approvals
- (2018) Matt Shirley DRUGS
- A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
- (2018) John Sarantopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.
- (2018) James F. Spicer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.
- (2018) Laurent Mortier et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma.
- (2018) Robert Hans Ingemar Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.
- (2018) Oddbjorn Straume et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).
- (2018) Jose A. Lopez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- (2018) Claire-Audrey Y. Bayan et al. Current Oncology Reports
- The age of enlightenment in melanoma immunotherapy
- (2018) Mark R. Albertini Journal for ImmunoTherapy of Cancer
- Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
- (2018) Luke D. Rothermel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
- (2018) Ahmad Tarhini et al. Journal for ImmunoTherapy of Cancer
- CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
- (2018) Francesco Schettini et al. Frontiers in Oncology
- Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
- (2017) Noelle L. Williams et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Sequencing Treatment in BRAFV600 Mutant Melanoma
- (2017) Douglas B. Johnson et al. JOURNAL OF IMMUNOTHERAPY
- The NF1 gene in tumor syndromes and melanoma
- (2017) Maija Kiuru et al. LABORATORY INVESTIGATION
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
- (2017) Yaohua Xue et al. NATURE MEDICINE
- The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
- (2017) Diana J. Uribe et al. PLoS One
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma
- (2017) Antoneicka L. Harris et al. Oncotarget
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
- (2017) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
- (2016) Cristina Corno et al. CURRENT MEDICINAL CHEMISTRY
- A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
- (2016) A. Varga et al. EUROPEAN JOURNAL OF CANCER
- CD28 Costimulation: From Mechanism to Therapy
- (2016) Jonathan H. Esensten et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
- (2016) Susan M. Hiniker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
- (2016) Alex A. Adjei et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
- (2016) Sofie Wilgenhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
- (2016) Antoine Millet et al. MEDICINAL RESEARCH REVIEWS
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
- (2016) Abhijit Ray et al. Oncotarget
- Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
- (2016) You-Take Oh et al. Scientific Reports
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
- (2016) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
- (2016) Andrew S. Brohl et al. Journal for ImmunoTherapy of Cancer
- The Receptor Tyrosine Kinase AXL in Cancer Progression
- (2016) Erinn Rankin et al. Cancers
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
- (2015) Gatien Moriceau et al. CANCER CELL
- Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
- (2015) N. Yamazaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds
- (2015) Fathima Shazna Thowfeik et al. CHEMBIOCHEM
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The multi-faceted roles of the PI3K-AKT pathway in melanoma
- (2015) Michael A Davies Journal of Translational Medicine
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
- (2015) Francesco Spagnolo et al. OncoTargets and Therapy
- Nivolumab in NSCLC: latest evidence and clinical potential
- (2015) Raghav Sundar et al. Therapeutic Advances in Medical Oncology
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
- (2015) Zeynep Eroglu et al. Therapeutic Advances in Medical Oncology
- Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor
- (2015) Paola Corazao-Rozas et al. Oncotarget
- Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.
- (2015) Mickaël Ohanna et al. Oncotarget
- Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
- (2015) Ludovica Ciuffreda et al. NEOPLASIA
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- Reactive Oxygen Species-Responsive Protein Modification and Its Intracellular Delivery for Targeted Cancer Therapy
- (2014) Ming Wang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
- (2014) A. M. Di Giacomo et al. ANNALS OF ONCOLOGY
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
- (2014) M. S. Carlino et al. CLINICAL CANCER RESEARCH
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An Activatable Prodrug for the Treatment of Metastatic Tumors
- (2014) Eun-Joong Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
- (2014) Richard Kefford et al. Journal of Translational Medicine
- Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
- (2014) Deborah JL Wong et al. Molecular Cancer
- Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
- (2014) L. N. Micel et al. MOLECULAR CANCER THERAPEUTICS
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
- (2013) L. N. Kwong et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
- (2013) D V Chan et al. GENES AND IMMUNITY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reactive oxygen species: from health to disease
- (2012) K Brieger et al. SWISS MEDICAL WEEKLY
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
- (2011) Peter D. Boasberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Rac signaling in breast cancer: A tale of GEFs and GAPs
- (2011) Eva Wertheimer et al. CELLULAR SIGNALLING
- Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
- (2011) Marialuisa Sensi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
- (2011) Sergey I Nikolaev et al. NATURE GENETICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- E6201 [(3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase (MEK)-1 and MEK Kinase-1: In Vitro Characterization of Its Anti-Inflammatory and Antihyperproliferative Activities
- (2009) M. Goto et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
- (2008) Joe W. Ramos INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now